Zheng Quan Zhi Xing·2025-08-13 11:11Core Viewpoint - The report evaluates the financial risk and operational status of Jizhong Energy Group Financial Co., Ltd., highlighting its compliance, risk management, and financial performance as of June 30, 2025 [1][13]. Financial Company Overview - Jizhong Energy Group Financial Co., Ltd. was established in 1998 and has undergone several capital increases, with a current registered capital of 55 billion RMB [1][3]. - The company has three main shareholders: Jizhong Energy Group, Jizhong Energy Co., Ltd., and North China Pharmaceutical Group, with respective ownership stakes of 45%, 35%, and 20% [2][3]. Compliance and Risk Control - The financial company operates under a robust governance structure, including a board of directors and various departments dedicated to risk control and internal auditing [4][12]. - It adheres to strict internal control measures and regulatory requirements, ensuring compliance with national financial regulations [5][12]. Operational Performance - As of June 30, 2025, the financial company reported total assets of 202.90 billion RMB and total liabilities of 142.28 billion RMB, with a net profit of 1.31 billion RMB for the first half of 2025 [13]. - The company maintains a capital adequacy ratio of 30.54% and a liquidity ratio of 65.78%, indicating strong financial health [13]. Risk Management Practices - The financial company has established comprehensive risk management policies, including credit risk assessment and monitoring systems for its lending activities [8][9]. - It has implemented various management measures to prevent internal operational risks and ensure the safety of client funds [6][7]. Shareholder Transactions - As of June 30, 2025, the shareholders' deposits and loans with the financial company were reported, with North China Pharmaceutical Group having a deposit balance of approximately 39.37 million RMB [14][16]. - The company has facilitated significant transactions, including commercial bill discounts totaling 4 billion RMB for North China Pharmaceutical Group [15]. Risk Assessment Conclusion - The financial company is deemed to operate within legal frameworks, with no significant violations of financial regulations reported [17]. - It has maintained a high level of loan loss provisions, ensuring that all member units are able to meet their repayment obligations without delays [17].